Merck reportedly plans to commit $250m as a limited partner in third-party venture capital funds in pharmaceuticals, although part of the money could also be invested directly, through its Merck Research Venture Fund, according to news provider In Vivo, which said the existing $125m Global Health Innovation Group had been doubled.
New York-listed drugs maker Merck has quadrupled its involvement in direct and indirect corporate venturing to $500m.
Merck reportedly plans to commit $250m as a limited partner in third-party venture capital funds in pharmaceuticals, although part of the money could also be invested directly, through its Merck Research Venture Fund, according to news provider In Vivo.
The Merck Research Venture Fund has made one undisclosed commitment already, In Vivo said, and will be initially run by the company’s senior vice-president,…
